Supportive arguments | |
---|---|
Primary rationales | |
Increased accessibility to NPMs | Increased freedom of choice |
Increased discretion | |
Decreased consumer safety | Shift in perception of NPMs |
Decreased counselling | |
Assistant rationales | |
Increased/reduced costs for consumers | Display, advertising and impulse buying |
Increased price competition | |
No need for scheme | No demand from consumers |
Works in neighboring countries | No complications in Sweden or Norway |
Populations similar to that in Denmark | |
Rationales not presented in documents | |
Economic interests | Increased sales of medicines |
Shift from generic to brand NPMs |